TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9024100

Group type: EXPERIMENTAL
Intervention: Micronized estradiol, 1.0 mg
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens, 0.625 mg
Number of subjects: 87

Group type: COMPARATOR
Intervention: Micronized estradiol, 0.5 mg
Number of subjects: 87
Study: 8328566

Group type: EXPERIMENTAL
Intervention: Sustained-release alprazolam (highest mean dose = 4.7 mg/day)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Sustained-release alprazolam
Number of subjects: 194
Study: 3819670

Group type: EXPERIMENTAL
Intervention: Internal Medicine Clinic
Number of subjects: 520

Group type: COMPARATOR
Intervention: Family Practice Clinic
Number of subjects: 520
Study: 30525929

Group type: EXPERIMENTAL
Intervention: Global signal regression (GSR)
Number of subjects: 0
Study: 26330286

Group type: EXPERIMENTAL
Intervention: Integrated care model
Number of subjects: 56

Group type: COMPARATOR
Intervention: Hospital outpatient clinics
Number of subjects: 56
Study: 24696051

Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 55

Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 55
Study: 23530786

Group type: EXPERIMENTAL
Intervention: Propofol 1 mg/kg alone (Group P)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Propofol 0.5 mg/kg and remifentanil 1 µg/kg (Group R)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Sevoflurane alone 6% (Group S)
Number of subjects: 39
Study: 20610555

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 microg/kg
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Morphine 100 microg/kg
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.75 microg/kg
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Morphine 50 microg/kg
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 109

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 109
Study: 18077795

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 4731

Group type: EXPERIMENTAL
Intervention: Hemorrhagic stroke as entry event
Number of subjects: 4731

Group type: EXPERIMENTAL
Intervention: Male patients
Number of subjects: 4731

Group type: EXPERIMENTAL
Intervention: Age (10 year increments)
Number of subjects: 4731

Group type: EXPERIMENTAL
Intervention: Stage 2 hypertension at last visit
Number of subjects: 4731
Study: 16606391

Group type: EXPERIMENTAL
Intervention: Automatic template
Number of subjects: 193

Group type: COMPARATOR
Intervention: Manual template
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Wavelet detection of VT
Number of subjects: 193
Study: 12720620

Group type: EXPERIMENTAL
Intervention: Oral supplementation (200 ml sweet or salty sip feed twice daily, providing 500 kcal, 21 g protein per day)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no oral supplementation)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Oral supplementation
Number of subjects: 80
Study: 10480775

Group type: EXPERIMENTAL
Intervention: Automated telephone disease management (ATDM) calls for 12 months
Number of subjects: 252
Study: 9110065

Group type: COMPARATOR
Intervention: Intravenous ganciclovir (5 mg/kg per day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral ganciclovir (500 mg six times a day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral ganciclovir (1000 mg three times a day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral ganciclovir
Number of subjects: 0
Study: 1901199

Group type: EXPERIMENTAL
Intervention: Z6noS (pyrazinamide for 6 months without streptomycin)
Number of subjects: 1386

Group type: EXPERIMENTAL
Intervention: Rifater (combined formulation of isoniazid, rifampin, and pyrazinamide)
Number of subjects: 1386

Group type: COMPARATOR
Intervention: Separate drugs (isoniazid, rifampin, and pyrazinamide administered separately)
Number of subjects: 1386
Study: 6759958

Group type: EXPERIMENTAL
Intervention: CDP Choline
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 31532574

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injections
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 30946312

Group type: EXPERIMENTAL
Intervention: Zao Ren An Shen capsule
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 30420286

Group type: EXPERIMENTAL
Intervention: PTH‐ICGT group
Number of subjects: 127

Group type: COMPARATOR
Intervention: Conventional naked eye group
Number of subjects: 127
Study: 26330424

Group type: EXPERIMENTAL
Intervention: Pre-operative statin therapy
Number of subjects: 2845

Group type: COMPARATOR
Intervention: Control group (no statin therapy)
Number of subjects: 2845
Study: 23805813

Group type: EXPERIMENTAL
Intervention: Scaling and root planing plus oral hygiene instruction
Number of subjects: 160
Study: 22297311

Group type: EXPERIMENTAL
Intervention: Five-session smoking reduction intervention
Number of subjects: 53

Group type: COMPARATOR
Intervention: Waiting list (control)
Number of subjects: 53
Study: 20473066

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50, 100, 200, or 400 mg/d
Number of subjects: 1808

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine
Number of subjects: 1808

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1808
Study: 17505516

Group type: EXPERIMENTAL
Intervention: Epirubicin-vinorelbine (Epi-Vnr)
Number of subjects: 482

Group type: COMPARATOR
Intervention: FEC100
Number of subjects: 482
Study: 15857225

Group type: EXPERIMENTAL
Intervention: Modem transfer of BG data
Number of subjects: 47

Group type: COMPARATOR
Intervention: Telephone communication of BG data
Number of subjects: 47
Study: 11885569

Group type: EXPERIMENTAL
Intervention: Acute tryptophan (TRP) depletion (100 g of an amino acid mixture without TRP)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (100 g of an amino acid mixture with TRP)
Number of subjects: 27
Study: 9579820

Group type: EXPERIMENTAL
Intervention: Noninvasive biomagnetic imaging using a multiple dipole model
Number of subjects: 4
Study: 7747571

Group type: EXPERIMENTAL
Intervention: Probenecid
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 2501032

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin patch (3.3 cm2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin patch (6.7 cm2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin patch (13.3 cm2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin patch (20 cm2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All patch sizes
Number of subjects: 30
Study: 28832429

Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogens (o-CEE; 0.45 mg/d)
Number of subjects: 653

Group type: EXPERIMENTAL
Intervention: Transdermal 17β-estradiol (t-E2; 50 μg/d) plus cyclic progesterone (200 mg)
Number of subjects: 653

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 653

Group type: EXPERIMENTAL
Intervention: Transdermal 17β-estradiol (t-E2)
Number of subjects: 653

Group type: EXPERIMENTAL
Intervention: Both HT formulations (o-CEE and t-E2)
Number of subjects: 653
Study: 27555179

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine (DEX) 1 μg/kg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine (DEX) 2 μg/kg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 90
Study: 24286456

Group type: EXPERIMENTAL
Intervention: 300 mg of GW766994 twice daily for 10 days followed by prednisone 30 mg for 5 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 60
Study: 22828538

Group type: EXPERIMENTAL
Intervention: Laparoscopic pyloromyotomy (Group A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Open pyloromyotomy (Group B)
Number of subjects: 30
Study: 20674830

Group type: EXPERIMENTAL
Intervention: Montelukast (5 mg, chewable tablet)
Number of subjects: 1162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1162
Study: 19025280

Group type: EXPERIMENTAL
Intervention: Stage-based behavioral counseling (SBC) provided by a nurse
Number of subjects: 60

Group type: COMPARATOR
Intervention: Educational digital video disc (DVD)
Number of subjects: 60
Study: 15992231

Group type: EXPERIMENTAL
Intervention: Meditation (30 minutes audiotape, twice a day for 12 weeks, plus weekly meetings)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (weekly meetings only)
Number of subjects: 19
Study: 12790212

Group type: EXPERIMENTAL
Intervention: Bispectral index monitoring
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no bispectral index monitoring)
Number of subjects: 60
Study: 11514924

Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 521

Group type: COMPARATOR
Intervention: Other therapy
Number of subjects: 521
Study: 9422018

Group type: EXPERIMENTAL
Intervention: Oral metronidazole (400 mg) twice daily for two days at 24 weeks of gestation
Number of subjects: 879
Study: 8181027

Group type: EXPERIMENTAL
Intervention: Organic nitrates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nitrates in combination with hydralazine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nitrate therapy without hydralazine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nitrates in patients treated with ACE inhibitors
Number of subjects: 0
Study: 3325255

Group type: EXPERIMENTAL
Intervention: Ofloxacin 100mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ofloxacin 200mg
Number of subjects: 60
Study: 2778203

Group type: EXPERIMENTAL
Intervention: Creative teaching methods (experimental groups)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Traditional lecture/demonstration format (control groups)
Number of subjects: 20
Study: 31934773

Group type: EXPERIMENTAL
Intervention: BackX™
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Laevo™
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (unsupported conditions)
Number of subjects: 18
Study: 31123075

Group type: EXPERIMENTAL
Intervention: Composite outcome MAPE (major adverse peritoneal events)
Number of subjects: 1720

Group type: COMPARATOR
Intervention: Individual outcomes (technical failure, peritonitis, peritoneal membrane deterioration)
Number of subjects: 1720
Study: 27602705

Group type: EXPERIMENTAL
Intervention: Text Messaging (TM) intervention with 2-way reminders about medication administration.
Number of subjects: 51

Group type: COMPARATOR
Intervention: Standard of care (control group).
Number of subjects: 51
Study: 26397085

Group type: EXPERIMENTAL
Intervention: Supervised spinal stabilization exercises (weekly physical therapy for 8 weeks)
Number of subjects: 34

Group type: COMPARATOR
Intervention: 1-time treatment followed by home exercises (unsupervised group)
Number of subjects: 34
Study: 23503913

Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol (15 mg/kg)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intravenous dipyrone (15 mg/kg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol and dipyrone
Number of subjects: 120
Study: 21054767

Group type: EXPERIMENTAL
Intervention: Exercise stress test
Number of subjects: 36
Study: 18834691

Group type: EXPERIMENTAL
Intervention: Counseling by Farquhar's six‐step method for 10 min after traditional oral hygiene instruction.
Number of subjects: 38

Group type: COMPARATOR
Intervention: Traditional oral hygiene instruction for 20 min.
Number of subjects: 38
Study: 17120180

Group type: EXPERIMENTAL
Intervention: 50 mg hydrochlorothiazide daily
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study: 15133938

Group type: EXPERIMENTAL
Intervention: Java mobile phone-based Home Helper care report creation support system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study: 11133604

Group type: EXPERIMENTAL
Intervention: NAD 6000 ventilator
Number of subjects: 20

Group type: COMPARATOR
Intervention: Servo 900C ventilator
Number of subjects: 20
Study: 9632123

Group type: EXPERIMENTAL
Intervention: 100 mg acarbose with 100 g sucrose
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo with 100 g sucrose
Number of subjects: 11
Study: 8534382

Group type: EXPERIMENTAL
Intervention: Sensitive/Tartar Control dentifrice (5.0% potassium nitrate, 1.3% soluble pyrophosphate, 1.5% PVM/MA copolymer, 0.243% sodium fluoride)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Sensodyne-F dentifrice (5% potassium nitrate, 0.76% sodium monofluorophosphate)
Number of subjects: 97
Study: 3205904

Group type: EXPERIMENTAL
Intervention: Intravenous oxytocin (OT) infusion
Number of subjects: 0
Study: 30947270

Group type: EXPERIMENTAL
Intervention: Flipped Classroom (FT) methodology
Number of subjects: 110

Group type: COMPARATOR
Intervention: Lecture-Based (LB) methodology
Number of subjects: 110
Study: 28889724

Group type: EXPERIMENTAL
Intervention: Combination treatment group (entecavir and adefovir dipivoxil)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Entecavir group
Number of subjects: 90
Study: 26306883

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) in addition to traditional physical therapy, administered three times per week for three months.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pulsed electromagnetic field (PEMF) in addition to traditional physical therapy, administered three times per week for three months.
Number of subjects: 30
Study: 23262158

Group type: EXPERIMENTAL
Intervention: VR-based exercise program (n=18) for 8 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (n=14) continuing daily routine for 8 weeks
Number of subjects: 32
Study: 22011432

Group type: EXPERIMENTAL
Intervention: Whey meal
Number of subjects: 11

Group type: COMPARATOR
Intervention: Cod meal
Number of subjects: 11

Group type: COMPARATOR
Intervention: Casein meal
Number of subjects: 11

Group type: COMPARATOR
Intervention: Gluten meal
Number of subjects: 11
Study: 18444531

Group type: EXPERIMENTAL
Intervention: Patient Controlled Analgesia (PCA)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Continuous Epidural Analgesia (Bupivacaine 0.125% + 5 microg/ml of Fentanyl, 6-10 ml/h)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Patient Controlled Epidural Analgesia (Bupivacaine 0.08% + 3 microg/ml of Fentanyl, 6 ml/h and bolus of 5 ml)
Number of subjects: 66
Study: 16165104

Group type: EXPERIMENTAL
Intervention: LI160 (2 x 750 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 12685136

Group type: EXPERIMENTAL
Intervention: Atrial septal pacing (Se-P)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Atrial appendage pacing (Ap-P)
Number of subjects: 56
Study: 10810847

Group type: EXPERIMENTAL
Intervention: Prenatal couple group intervention (TG)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 35
Study: 8772586

Group type: EXPERIMENTAL
Intervention: Physiological dose of GH (0.04 U/kg)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Supraphysiological dose of GH (0.08 U/kg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 1739068

Group type: EXPERIMENTAL
Intervention: Light-cured glass ionomer (Zionomer) tested at 1 hour
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Light-cured glass ionomer (Zionomer) tested at 24 hours
Number of subjects: 52

Group type: COMPARATOR
Intervention: Chemically cured glass ionomer (Ketac-Bond) tested at 1 hour
Number of subjects: 52

Group type: COMPARATOR
Intervention: Chemically cured glass ionomer (Ketac-Bond) tested at 24 hours
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Both glass ionomers tested at 1 hour and 24 hours
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Light-cured glass ionomer (Zionomer) tested at 1 hour and 24 hours
Number of subjects: 52

Group type: COMPARATOR
Intervention: Chemically cured glass ionomer (Ketac-Bond) tested at 1 hour and 24 hours
Number of subjects: 52
Study: 6503959

Group type: EXPERIMENTAL
Intervention: Pre- and postoperative radiotherapy (total dose 5000 rads, with 3000 rads preoperative) and adjuvant chemotherapy (FT-207, 600mg/day for over 3 months) in group A.
Number of subjects: 19

Group type: COMPARATOR
Intervention: Postoperative radiotherapy alone in group B.
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Pre- and postoperative radiotherapy in group A.
Number of subjects: 19
Study: 31721812

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (20 Hz) for abdominal muscles, 60 sessions over 12 weeks (23 min/session, 5 days/week)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group continued usual training
Number of subjects: 24
Study: 30540367

Group type: EXPERIMENTAL
Intervention: Tomography and Biomechanical Index (TBI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Belin/Ambrósio Enhanced Ectasia Display (BAD‐D) index
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Corvis Biomechanical Index (CBI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cut-offs from Ambrósio et al. (2017)
Number of subjects: 0
Study: 27288812

Group type: EXPERIMENTAL
Intervention: Riluzole
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 24813670

Group type: EXPERIMENTAL
Intervention: Classroom-based cognitive behaviour therapy (CBT)
Number of subjects: 3357

Group type: COMPARATOR
Intervention: Usual school provision of Personal Social and Health Education (Control)
Number of subjects: 3357
Study: 23203358

Group type: EXPERIMENTAL
Intervention: Life Goals Collaborative Care (LGCC)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Enhanced treatment as usual
Number of subjects: 68
Study: 21047406

Group type: EXPERIMENTAL
Intervention: Oral beta-blockers at admission
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Oral beta-blockers before hospital discharge
Number of subjects: 314

Group type: COMPARATOR
Intervention: No beta-blocker therapy
Number of subjects: 314
Study: 19041594

Group type: EXPERIMENTAL
Intervention: Woman Abuse Screening Tool (WAST)
Number of subjects: 5607

Group type: COMPARATOR
Intervention: Composite Abuse Scale (CAS)
Number of subjects: 5607

Group type: EXPERIMENTAL
Intervention: Characteristics associated with being positive on both WAST and CAS
Number of subjects: 5607
Study: 16109054

Group type: COMPARATOR
Intervention: eletriptan 40 mg
Number of subjects: 19

Group type: COMPARATOR
Intervention: eletriptan 20 mg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: sumatriptan 100 mg
Number of subjects: 19
Study: 12439034

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Number of subjects: 512

Group type: COMPARATOR
Intervention: No G-CSF
Number of subjects: 512
Study: 10088733

Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine 0.5% ophthalmic solution (Acular) administered four times daily for 14 days
Number of subjects: 102

Group type: COMPARATOR
Intervention: Vehicle solution administered four times daily for 14 days
Number of subjects: 102
Study: 7487290

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 35

Group type: COMPARATOR
Intervention: High dose aprotinin
Number of subjects: 35
Study: 2181254

Group type: EXPERIMENTAL
Intervention: Intravaginal brachytherapy
Number of subjects: 108

Group type: COMPARATOR
Intervention: Intraoperative rinsing of the vagina with alcohol and suturing of the cervical canal
Number of subjects: 108
Study: 624779

Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Bumetanide
Number of subjects: 11
Study: 31609707

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (MgSO4) and melatonin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Melatonin only
Number of subjects: 60
Study: 28559400

Group type: EXPERIMENTAL
Intervention: β-blockers
Number of subjects: 2527

Group type: COMPARATOR
Intervention: No β-blockers
Number of subjects: 2527
Study: 26386784

Group type: EXPERIMENTAL
Intervention: FFR-guided PCI with new-generation stents
Number of subjects: 0

Group type: COMPARATOR
Intervention: CABG
Number of subjects: 0
Study: 22612557

Group type: EXPERIMENTAL
Intervention: MobileMums intervention
Number of subjects: 88

Group type: COMPARATOR
Intervention: Minimal-contact control condition
Number of subjects: 88
Study: 21903907

Group type: EXPERIMENTAL
Intervention: Enalapril (ACE-I)
Number of subjects: 6337

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6337

Group type: EXPERIMENTAL
Intervention: Enalapril (ACE-I) in patients who continued therapy despite early WRF
Number of subjects: 6337
Study: 18155200

Group type: EXPERIMENTAL
Intervention: Hysteroscopic surgery to correct uterine septa, intrauterine synechiae, and myomas
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Removal of endometrial polyps
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical treatment for complex congenital anomalies (e.g., unicornuate uterus, uterus didelphys)
Number of subjects: 0
Study: 16792136

Group type: EXPERIMENTAL
Intervention: Intermittent oral alfacalcidol (2 microg after each dialysis session)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Continuous oral alfacalcidol (1 microg given 6 days/week)
Number of subjects: 34
Study: 12755658

Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 11113728

Group type: EXPERIMENTAL
Intervention: Sildenafil (100 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 1729064

Group type: EXPERIMENTAL
Intervention: Oral theophylline
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination of theophylline and salbutamol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 12
Study: 6398510

Group type: EXPERIMENTAL
Intervention: 0.5 mg dihydroergotamine + 5000 U heparin
Number of subjects: 46

Group type: COMPARATOR
Intervention: 5000 U heparin alone (controls)
Number of subjects: 46
Study: 30655255

Group type: EXPERIMENTAL
Intervention: Custom administration of a standard dose of gadobutrol
Number of subjects: 83
Study: 30607120

Group type: EXPERIMENTAL
Intervention: High-fidelity (hf) e-learning module
Number of subjects: 18

Group type: COMPARATOR
Intervention: Low-fidelity (lf) e-learning module
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: High-fidelity (hf) and Low-fidelity (lf) e-learning modules
Number of subjects: 18
Study: 27109326

Group type: COMPARATOR
Intervention: Standard CBT
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Experimental CBT
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Mid-therapy response level
Number of subjects: 35